These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 36375225

  • 1. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis.
    Chaivichacharn P, Avihingsanon A, Gatechompol S, Ubolyam S, Punyawudho B.
    Drug Metab Pharmacokinet; 2022 Dec; 47():100478. PubMed ID: 36375225
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change.
    Jacobs TG, Mumbiro V, Chitsamatanga M, Namuziya N, Passanduca A, Domínguez-Rodríguez S, Tagarro A, Nathoo KJ, Nduna B, Ballesteros A, Madrid L, Mujuru HA, Chabala C, Buck WC, Rojo P, Burger DM, Moraleda C, Colbers A, EMPIRICAL Clinical Trial Group, EMPIRICAL Clinical Trial Group.
    J Acquir Immune Defic Syndr; 2023 May 01; 93(1):42-46. PubMed ID: 36724434
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS, Goa KL.
    Drugs; 2003 May 01; 63(8):769-802. PubMed ID: 12662125
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
    Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron H.
    PLoS One; 2012 May 01; 7(3):e32173. PubMed ID: 22412856
    [Abstract] [Full Text] [Related]

  • 13. Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.
    Chupradit S, Wamalwa DC, Maleche-Obimbo E, Kekitiinwa AR, Mwanga-Amumpaire J, Bukusi EA, Nyandiko WM, Mbuthia JK, Swanson A, DNDi Clinical TeamDrugs for Neglected Diseases Initiative, Geneva, Switzerland.Drugs for Neglected Diseases Initiative, Nairobi, Kenya.Drugs for Neglected Diseases Initiative, Bethesda, Maryland, USA., Cressey TR, Punyawudho B, Musiime V, LIVING Study Team.
    Clin Pharmacol Ther; 2024 May 01; 115(5):1105-1113. PubMed ID: 38247190
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
    Ouedraogo HG, Matteelli A, Sulis G, Compaore TR, Diagbouga S, Tiendrebeogo S, Roggi A, Cisse K, Giorgetti PF, Villani P, Sangare L, Simpore J, Regazzi M, Kouanda S.
    Ann Clin Microbiol Antimicrob; 2020 Jan 22; 19(1):3. PubMed ID: 31969147
    [Abstract] [Full Text] [Related]

  • 15. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
    Rabie H, Tikiso T, Lee J, Fairlie L, Strehlau R, Bobat R, Liberty A, McIlleron H, Andrieux-Meyer I, Cotton M, Lallemant M, Denti P.
    Antimicrob Agents Chemother; 2020 Apr 21; 64(5):. PubMed ID: 32071055
    [Abstract] [Full Text] [Related]

  • 16. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug 21; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
    Ramautarsing RA, van der Lugt J, Gorowara M, Sophonphan J, Ananworanich J, Lange JM, Burger DM, Phanuphak P, Ruxthungtham K, Avihingsanon A.
    Antivir Ther; 2013 Aug 21; 18(2):249-52. PubMed ID: 22908131
    [Abstract] [Full Text] [Related]

  • 18. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.
    Antivir Ther; 2007 Aug 21; 12(6):963-9. PubMed ID: 17926651
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.